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The typical clinical symptoms of the patients who suffered from the novel viral 
pneumonia were fever, cough, and myalgia or fatigue with abnormal chest CT, and the 
less common symptoms were sputum production, headache, hemoptysis, and diarrhea. 
This new infectious agent is more likely to affect older males to cause severe respiratory 
diseases. Major risk factors for severe illness and mortality from COVID-19 are age, 
comorbidities such as: heart disease, hypertension, prior stroke, diabetes, chronic lung 
disease, and chronic kidney disease and associated with adverse outcomes. Loss of taste 
and smell preceding the onset of respiratory symptoms has been reported.
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1. Introduction
This chapter will discuss the clinical features of COVID-19. The epidemiology, 
virology, prevention, and diagnosis of COVID-19 are discussed elsewhere.
1.1 Asymptomatic infections
Asymptomatic infections have been well documented. One review estimated 
that 33 percent of people with SARS-CoV-2 infection never develop symptoms [1]. 
This estimate was based on four large population-based, cross-sectional surveys, 
among which the median proportion of individuals who had no symptoms at the 
time of a positive test was 46 percent (range 43 to 77 percent), and on 14 longi-
tudinal studies, among which a median of 73 percent of initially asymptomatic 
individuals remained so on follow-up. However, there is still uncertainty around the 
proportion of asymptomatic infections, with a wide range reported across studies. 
Additionally, the definition of “asymptomatic” may vary across studies, depending 
on which specific symptoms were assessed.
Patients with asymptomatic infection may have objective clinical abnormalities. 
As an example, in a study of 24 patients with asymptomatic infection who all under-
went chest computed tomography (CT), 50 percent had typical ground-glass opaci-
ties or patchy shadowing, and another 20 percent had atypical imaging abnormalities 
[2]. Five patients developed low-grade fever, with or without other typical symptoms, 
a few days after diagnosis. In another study of 55 patients with asymptomatic infec-
tion identified through contact tracing, 67 percent had CT evidence of pneumonia on 
admission; only two patients developed hypoxia, and all recovered [3].
As above, some individuals who are asymptomatic at the time of diagnosis go 
on to develop symptoms (ie, they were actually presymptomatic). In one study, 
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symptom onset occurred a median of four days (range of three to seven) after the 
initial positive RT-PCR test [4].
1.2 Severity of symptomatic infection
1.2.1 Spectrum of severity and case fatality rates
The spectrum of symptomatic infection ranges from mild to critical; most infec-
tions are not severe. Specifically, disease severity may be classified as:
• Mild disease (no or mild pneumonia) was reported in 81 percent of cases.
• Severe disease (eg, with dyspnea, hypoxia, or > 50 percent lung involvement 
on imaging within 24 to 48 hours) was reported in 14 percent.
• Critical disease (eg, with respiratory failure, shock, or multiorgan dysfunc-
tion) was reported in 5 percent.
• The overall case fatality rate was 2.3 percent; no deaths were reported among 
noncritical cases.
Since many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infections are asymptomatic, the infection fatality rate (ie, the estimated mortal-
ity rate among all individuals with infection) is considerably lower and has been 
estimated by some analyses to be between 0.5 and 1 percent. Conversely, the 
reported case fatality rates are likely underestimates of the true case fatality rates, as 
many fatal infections are undiagnosed. Neither the case fatality rate nor the infec-
tion fatality rate account for the full burden of the pandemic, which includes excess 
mortality from other conditions because of delayed care, overburdened health care 
systems, and social determinants of health.
1.2.2 Risk factors for severe illness
Severe illness can occur in otherwise healthy individuals of any age, but it 
predominantly occurs in adults with advanced age or certain underlying medical 
comorbidities. Specific demographic features and laboratory abnormalities have 
also been associated with severe disease.
1.2.3 Increasing age
Individuals of any age can acquire SARS-CoV-2 infection, although adults of 
middle age and older are most commonly affected, and older adults are more likely 
to have severe disease.
In several cohorts of hospitalized patients with confirmed COVID-19, the 
median age ranged from 49 to 56 years.
Older age is also associated with increased mortality. In contrast, individuals 
aged 18 to 34 years accounted for only 5 percent of adults hospitalized for COVID-
19 in a large health care database study and had a mortality rate of 2.7 percent; 
morbid obesity, hypertension, and male sex were associated with mortality in that 
age group.
Symptomatic infection in children and adolescents appears to be relatively 
uncommon; when it occurs, it is usually mild, although a small proportion experi-
ence severe and even fatal disease.
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1.2.4 Comorbidities
Comorbidities and other conditions that have been associated with severe 
illness and mortality include Cardiovascular disease, Diabetes mellitus, Chronic 
obstructive pulmonary disease and other lung diseases, Cancer (in particular 
hematologic malignancies, lung cancer, and metastatic disease), Chronic kidney 
disease, Solid organ or hematopoietic stem cell transplantation, Obesity and 
Smoking.
1.2.5 Socioeconomic background and sex
Certain demographic features have also been associated with more severe 
illness. Males have comprised a disproportionately high number of critical cases 
and deaths in multiple cohorts worldwide. Black, Hispanic, and South Asian 
individuals comprise a disproportionately high number of infections and deaths 
due to COVID-19, likely related to underlying disparities in the social determinants 
of health.
1.2.6 Laboratory abnormalities
Particular laboratory features have also been associated with worse outcomes. 
These include, Lymphopenia, Thrombocytopenia, Elevated liver enzymes, Elevated 
lactate dehydrogenase (LDH), Elevated inflammatory markers (eg, C-reactive 
protein [CRP], ferritin) and inflammatory cytokines (ie, interleukin 6 [IL-6] and 
tumor necrosis factor [TNF]-alpha), Elevated D-dimer (>1 mcg/mL), Elevated pro-
thrombin time (PT), Elevated troponin, Elevated creatine phosphokinase (CPK), 
Acute kidney injury. Deficiencies in certain micronutrients, in particular vitamin D, 
have been associated with more severe disease in observational studies.
1.2.7 Viral factors
Patients with severe disease have also been reported to have higher viral RNA 
levels in respiratory specimens than those with milder disease, although some 
studies have found no association between respiratory viral RNA levels and dis-
ease severity. Detection of viral RNA in the blood has been associated with severe 
disease, including organ damage (eg, lung, heart, and kidney), coagulopathy, and 
mortality.
1.2.8 Genetic factors
Host genetic factors are also being evaluated for associations with severe disease. 
One genome-wide association study identified a relationship between polymor-
phisms in the genes encoding the ABO blood group and respiratory failure from 
COVID-19 (type A associated with a higher risk) [5]. Type O has been associated 
with a lower risk of both infection and severe disease [6].
1.3 Incubation period
The incubation period for COVID-19 is generally within 14 days following 
exposure, with most cases occurring approximately four to five days after exposure. 
However, determinations of the incubation period can be imprecise and may differ 
by the method of assessing exposure and the specific calculations used for the 
estimate.
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1.4 Initial presentation
Among patients with symptomatic COVID-19, cough, myalgias, and headache 
are the most commonly reported symptoms. Other features, including diarrhea, 
sore throat, and smell or taste abnormalities. Pneumonia is the most frequent seri-
ous manifestation of infection, characterized primarily by fever, cough, dyspnea, 
and bilateral infiltrates on chest imaging. Although some clinical features (in par-
ticular smell or taste disorders) are more common with COVID-19 than with other 
viral respiratory infections, there are no specific symptoms or signs that can reliably 
distinguish COVID-19. However, development of dyspnea approximately one week 
after the onset of initial symptoms may be suggestive of COVID-19.
The range of associated symptoms includes; Cough in 50 percent, Fever in 43 
percent, Myalgia in 36 percent, Headache in 34 percent, Dyspnea in 29 percent, Sore 
throat in 20 percent, Diarrhea in 19 percent, Nausea/vomiting in 12 percent, Loss of 
smell or taste, abdominal pain, and rhinorrhea in fewer than 10 percent each.
In a meta-analysis of observational studies, the pooled prevalence estimates for 
smell or taste abnormalities were 52 and 44 percent, respectively (although rates 
ranged from 5 to 98 percent across studies) [7]. However, the rate of objective smell 
or taste anomalies may be lower than the self-reported rates.
Most subjective smell and taste disorders associated with COVID-19 do not 
appear to be permanent; in a follow-up survey of the 202 patients with COVID-19, 
89 percent of those who noted smell or taste alterations reported resolution or 
improvement by four weeks [8].
Although not noted in the majority of patients, gastrointestinal symptoms (eg, 
nausea and diarrhea) may be the presenting complaint in some patients. In a sys-
tematic review of studies reporting on gastrointestinal symptoms in patients with 
confirmed COVID-19, the pooled prevalence was 18 percent overall, with diarrhea, 
nausea/vomiting, or abdominal pain reported in 13, 10, and 9 percent, respectively [9].
Nonspecific signs and symptoms, such as falls, general health decline, and 
delirium, have been described in older adults, particularly those over 80 years old 
and those with underlying neurocognitive impairments.
Dermatologic findings in patients with COVID-19 are not well characterized. 
There have been reports of maculopapular, urticarial, and vesicular eruptions and 
transient livedo reticularis. Reddish-purple nodules on the distal digits similar in 
appearance to pernio have also been described, mainly in children and young adults 
with documented or suspected COVID-19.
1.5 Acute course and complications
Symptomatic infection can range from mild to critical. Some patients with ini-
tially non-severe symptoms may progress over the course of a week. In one study of 
138 patients hospitalized in Wuhan for pneumonia due to severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), dyspnea developed after a median of five 
days since the onset of symptoms, and hospital admission occurred after a median 
of seven days of symptoms [10].
1.5.1 Recovery and long-term sequelae
The time to recovery from COVID-19 is highly variable and depends on age and 
pre-existing comorbidities in addition to illness severity. Individuals with mild 
infection are expected to recover relatively quickly (eg, within two weeks) whereas 
many individuals with severe disease have a longer time to recovery (eg, two to 
three months). The most common persistent symptoms include fatigue, dyspnea, 
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chest pain, cough, and cognitive deficits. Data also suggest the potential for ongoing 
respiratory impairment and cardiac sequelae. Some patients who have recovered 
from COVID-19 have persistently or recurrently positive nucleic acid amplification 
tests (NAATs) for SARS-CoV-2. Although recurrent infection or reinfection cannot 
be definitively ruled out in these settings, evidence suggests that these are unlikely.
2. Special populations
2.1 Pregnant and breastfeeding women
The general approach to prevention, evaluation, diagnosis, and treatment of 
pregnant women with suspected COVID-19 is largely similar to that in nonpregnant 
individuals.
2.2 Children
Symptomatic infection in children appears to be relatively uncommon; when it 
occurs, it is usually mild, although severe cases have been reported.
2.3 People with HIV
The impact of HIV infection on the natural history of COVID-19 is uncertain. 
The clinical features appear the same as in the general population. However, many 
of the comorbid conditions associated with severe COVID-19 (eg, cardiovascular 
disease) occur frequently among persons with HIV, and it is unclear whether these 
or other potential confounding features, rather than HIV infection itself, contribute 
to the risk. Low CD4 cell count may be associated with critical illness and death in 
patients with HIV and COVID-19.
3. Oral manifestations associated with COVID-19
Although many physicians continue to question the direct link between SARS-
CoV-2 and oral disease, studies suggest that the mouth might be the most vulner-
able area to this virus due to the abundance of the ACE2 (angiotensin converting 
enzyme) receptor in oral tissue.
The ACE2 receptor has been well-documented to be the target receptor of the 
SARS-CoV-2 virus and the portal of entry into the human cell. Compared with 
other oral tissues, cells of the salivary glands, tongue, and tonsils carry the most 
RNA linked to proteins that the SARS-CoV-2 virus needs to infect cells [11].
Oral manifestations associated with COVID-19 infection includes:
3.1 Gingival inflammation
Bleeding and inflammation in oral tissue have been suggested to be a result 
of a generalized increase in inflammation due to elevated levels of cytokines 
and interleukins initiated by the SARS CoV-2 virus. COVID-19 disease sever-
ity has been linked to an immune dysregulation, leading to a cytokine storm. 
Periodontal disease can increase levels of circulating cytokines, particularly 
interleukin-6 (IL-6), which has been implicated as one of the major interleukins 
leading to the cytokine storm [12] and periodontal disease is currently being 
examined as a possible contributing disease toward COVID-19 severity.
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3.2 Xerostomia (dry mouth)
COVID-19 has been suggested to cause dry mouth for a variety of reasons. The 
most common is mouth breathing by an individual due to mask use. Mouth breath-
ing can desiccate oral tissue especially without frequent hydration. Studies suggest 
that another biologic mechanism involves viral entry into the salivary glands, which 
are known to be abundant in the ACE2 receptor [13].
3.3 Oral ulcerations and gingival tissue breakdown
COVID-19 has been associated with vascular anomalies due to viral damage 
of blood vessels a process whereby the virus gains entry into the endothelial cells 
that line blood vessels via the ACE2 receptor and damages them. Tissue necrosis, 
including oral ulcerations, can be the result of vessel damage. Ulceration and tissue 
damage can be further exacerbated by increased inflammation and upregulation in 
inflammatory markers due to the SARS-CoV-2 virus [14].
3.4 Loss of taste and smell
A sudden onset in loss of taste (ageusia) and smell (anosmia) are two symptoms 
that can be the earliest indicators of COVID-19. An average of 47% (up to 80%) 
of individuals who test positive for COVID-19 can have subjective complaints of 
taste and smell loss, particularly in cases of asymptomatic or mild disease [15]. The 
mechanism behind this loss is suspected to be viral disruption of cranial nerves 1, 
7, 9, and 10, as well as the supporting cells of neural transmission [16]. In addition, 
because the tongue has an abundance of ACE2 receptors, direct viral entry into 
tongue cells is possible.
4. Laboratory findings
Common laboratory findings among hospitalized patients with COVID-
19 include lymphopenia, elevated aminotransaminase levels, elevated lactate 
dehydrogenase levels, elevated inflammatory markers (eg, ferritin, C-reactive 
protein, and erythrocyte sedimentation rate), and abnormalities in coagulation 
tests. Lymphopenia is especially common, even though the total white blood cell 
count can vary. On admission, many patients with pneumonia have normal serum 
procalcitonin levels; however, in those requiring ICU care, they are more likely to 
be elevated. Several laboratory features, including high D-dimer levels and more 
severe lymphopenia, have been associated with critical illness or mortality.
5. Imaging findings
5.1 Chest radiographs
Chest radiographs may be normal in early or mild disease. Common abnormal 
radiograph findings were consolidation and ground-glass opacities, with bilateral, 
peripheral, and lower lung zone distributions; lung involvement increased over the 
course of illness, with a peak in severity at 10 to 12 days after symptom onset.
Spontaneous pneumothorax has also been described, although it is relatively 
uncommon.
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5.2 Chest CT
Although chest computed tomography (CT) may be more sensitive than chest 
radiograph and some chest CT findings may be characteristic of COVID-19, no 
finding can completely rule in or rule out the possibility of COVID-19. Chest CT in 
patients with COVID-19 most commonly demonstrates ground-glass opacification 
with or without consolidative abnormalities, consistent with viral pneumonia. In a 
systematic review of studies evaluating the chest CT findings in over 2700 patients 
with COVID-19, the following abnormalities were noted: Ground-glass opacifica-
tions, Ground-glass opacifications with mixed consolidation, adjacent pleural 
thickening, Interlobular septal thickening, Air bronchograms. Other less common 
findings were a crazy paving pattern (ground-glass opacifications with superim-
posed septal thickening), bronchiectasis, pleural effusion, pericardial effusion, and 
lymphadenopathy. Chest CT abnormalities in COVID-19 are often bilateral, have a 
peripheral distribution, and involve the lower lobes.
Although these findings are common in COVID-19, they are not unique to it and 
are frequently seen with other viral pneumonias.
As with chest radiographs, chest CT may be normal soon after the onset of 
symptoms, with abnormalities more likely to develop over the course of illness. 
However, chest CT abnormalities have also been identified in patients prior to 
the development of symptoms and even prior to the detection of viral RNA from 
upper respiratory specimens. Among patients who clinically improve, resolution of 
radiographic abnormalities may lag behind improvements in fever and hypoxia.
5.3 Lung ultrasound
Findings on lung ultrasound in patients with documented COVID-19 have 
included thickening, discontinuation, and interruption of the pleural line; B lines 
visible under the pleura that appear discrete, multifocal, or confluent; patchy, strip, 
and nodular consolidations; and air bronchogram signs in the consolidations.
6. Complications of COVID-19
Several complications of COVID-19 have been described:
6.1 Respiratory failure
Acute respiratory distress syndrome (ARDS) is the major complication in 
patients with severe disease and can manifest shortly after the onset of dyspnea.
6.2 Cardiac and cardiovascular complications
Other complications have included arrhythmias, myocardial injury, heart 
failure, and shock.
6.3 Thromboembolic complications
Venous thromboembolism (VTE), including extensive deep vein thrombosis 
(DVT) and pulmonary embolism (PE), is common in severely ill patients with 
COVID-19, particularly among patients in the intensive care unit (ICU), among 
whom reported rates have ranged from 10 to 40 percent. Arterial thrombotic 
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events, including acute stroke (even in patients younger than 50 years of age with-
out risk factors) and limb ischemia, have also been reported.
6.4 Neurologic complications
Encephalopathy is a common complication of COVID-19, particularly among 
critically ill patients; Stroke, movement disorders, motor and sensory deficits, 
ataxia, and seizures occur less frequently.
6.5 Inflammatory complications
Some patients with severe COVID-19 have laboratory evidence of an exuberant 
inflammatory response, with persistent fevers, elevated inflammatory markers 
(eg, D-dimer, ferritin), and elevated proinflammatory cytokines; these labora-
tory abnormalities have been associated with critical and fatal illnesses. Although 
these features had been likened to cytokine release syndrome (eg, in response to T 
cell immunotherapy), the levels of proinflammatory cytokines in COVID-19 are 
substantially lower than those seen with cytokine release syndrome as well as with 
sepsis. Other inflammatory complications and auto-antibody-mediated manifesta-
tions have been described.
Guillain-Barré syndrome may occur, with onset 5 to 10 days after initial symp-
toms. A multisystem inflammatory syndrome with clinical features similar to those 
of Kawasaki disease and toxic shock syndrome has also been described in children 
with COVID-19. In the rare adults in whom it has been reported, this syndrome 
has been characterized by markedly elevated inflammatory markers and multi-
organ dysfunction (in particular cardiac dysfunction), but minimal pulmonary 
involvement.
6.6 Secondary infections
Secondary infections do not appear to be common complications of COVID-
19 overall, the reported rate of bacterial or fungal coinfections was 8 percent; 
these included mainly respiratory infections and bacteremia. Several reports have 
described presumptive invasive aspergillosis among immunocompetent patients 
with ARDS from COVID-19, although the frequency of this complication is 
uncertain.
Autopsy studies have noted detectable SARS-CoV-2 RNA (and, in some cases, 
antigen) in the kidneys, liver, heart, brain, and blood in addition to respiratory 
tract specimens, suggesting that the virus disseminates systemically in some cases; 
whether direct viral cytopathic effects at these sites contribute to the complications 
observed is uncertain.
7. Summary
The clinical spectrum of severe acute respiratory syndrome coronavirus 2 
(SARS-COV-2) infection ranges from asymptomatic infection to critical and fatal 
illness. The proportion of infections that are asymptomatic is uncertain, as the defi-
nition of “asymptomatic” varies across studies and longitudinal follow-up to iden-
tify those who ultimately develop symptoms is often not performed. Nevertheless, 
some estimates suggest that up to 40 percent of infections are asymptomatic.
Most symptomatic infections are mild. Severe disease (eg, with hypoxia and 
pneumonia) has been reported in 15 to 20 percent of symptomatic infections; it 
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can occur in otherwise healthy individuals of any age, but predominantly occurs in 
adults with advanced age or certain underlying medical comorbidities.
Cough, myalgias, and headache are the most commonly reported symptoms. 
Other features, including diarrhea, sore throat, and smell or taste abnormalities, 
are also well described. Pneumonia, with fever, cough, dyspnea, and infiltrates on 
chest imaging, is the most frequent serious manifestation of infection. There are no 
specific clinical features that can yet reliably distinguish COVID-19 from other viral 
respiratory infections.
Certain laboratory features, such as lymphopenia, elevated D-dimer, and 
elevated inflammatory markers have been associated with severe COVID-19.
Acute respiratory distress syndrome (ARDS) is the major complication in 
patients with severe disease and can manifest shortly after the onset of dyspnea. 
Other complications of severe illness include thromboembolic events, acute cardiac 
injury, kidney injury, and inflammatory complications.
The possibility of COVID-19 should be considered primarily in patients with 
compatible symptoms, in particular fever and/or respiratory tract symptoms, who 
reside in or have traveled to areas with community transmission or who have had 
recent close contact with a confirmed or suspected individual with COVID-19. 
All symptomatic patients with suspected SARS-CoV-2 infection should undergo 
testing.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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